The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses results from the Phase II MAGNOLIA trial (NCT03846427), which evaluated the safety and efficacy of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). Dr Linton highlights the long-term safety data and high overall response rates (ORR) observed with this agent. When compared to pooled data on patients treated with ibrutinib, zanubrutinib demonstrated lower cardiovascular toxicity and was well tolerated, providing a promising novel therapeutic approach for patients with R/R MZL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
